Adverse Effects of Dupilumab for Chronic Rhinosinusitis With Nasal Polyposis: Real‐World Single Institution Experience
The Laryngoscope · 2025
DOI: 10.1002/lary.32359 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, 2025. Verfasst von Avivah J Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Duke University School of Medicine, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Sinusitis, Antibodies, Monoclonal, Humanized, Rhinitis, Nasal Polyps. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCD NIH HHS, National Institute on Deafness and Other Communication Disorders.
Abstract (Originalsprache)
Objective
Phase III trials have shown that dupilumab is an effective and well‐tolerated adjunct treatment for patients with uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). However, real‐world data pertaining to tolerability and adverse effects (AE) are lacking. The goal of this study is to investigate AE incidence, timing, and medication discontinuation.
Methods
This is a retrospective cohort study at a single tertiary care institution. Patients initiating treatment with dupilumab for CRSwNP over a four‐year period (2020–2023) with at least six months of follow‐up were included. Univariate analysis and multivariable logistic regression were performed to investigate relevant clinical factors associated with AEs. Univariate analysis was also performed to determine factors associated with discontinuation due to AEs.
Results
115 patients received at least one dose of dupilumab. Mean age (SD) was 51.0 (14.9) years, and 44% were female. 39 patients reported at least one AE, with 15 having more than one AE. 15 patients (13.0%) discontinued the medication due to an AE. Ocular AEs were the most common (15), followed by injection site reactions (10), musculoskeletal (9), and non‐injection site skin reactions (8). Female sex was significantly associated with AEs and discontinuation due to AEs.
Conclusion
While dupilumab is an effective treatment option for uncontrolled CRSwNP, the incidence of AEs and discontinuation rates were higher than reported in Phase III trials. Additional real‐world data pertaining to AEs can aid in clinical decision‐making and patient counseling. Level of Evidence 4
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Duke University School of Medicine, Durham, North Carolina, USA.
- Department of Head and Neck Surgery and Communication Sciences, Duke University School of Medicine, Durham, North Carolina, USA.
ORCID-Profile: Avivah J Wang, Bradley J Goldstein, David W Jang
Förderung
- NIDCD NIH HHS
- National Institute on Deafness and Other Communication Disorders
Zitieren
APA
Wang, A. J., Jiang, R., Runyan, T., Abi Hachem, R., Goldstein, B. J., & Jang, D. W. (2025). Adverse Effects of Dupilumab for Chronic Rhinosinusitis With Nasal Polyposis: Real‐World Single Institution Experience. The Laryngoscope. https://doi.org/10.1002/lary.32359
Vancouver
Wang AJ, Jiang R, Runyan T, Abi Hachem R, Goldstein BJ, Jang DW. Adverse Effects of Dupilumab for Chronic Rhinosinusitis With Nasal Polyposis: Real‐World Single Institution Experience. The Laryngoscope. 2025. doi:10.1002/lary.32359
BibTeX
@article{Wang2025,
author = {Wang, Avivah J and Jiang, Rong and Runyan, Tami and Abi Hachem, Ralph and Goldstein, Bradley J and Jang, David W},
title = {Adverse Effects of Dupilumab for Chronic Rhinosinusitis With Nasal Polyposis: Real‐World Single Institution Experience},
journal = {The Laryngoscope},
year = {2025},
doi = {10.1002/lary.32359}
}
EUVIMED